Our data suggest that enhancing macrophage efferocytosis by exogenous aPC treatment or by biased PAR1 agonists may provide promising therapeutic approaches for ameliorating diabetes-induced atherosclerosis. The gene discussed is F2R; the disease is diabetes mellitus.